Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Interventional × Malignant Disease × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 2002 Carcinoma, Non-Small-Cell Lung 1215 Breast Neoplasms 1209 Leukemia, Myeloid, Acute 957 Neoplasm Metastasis 895 Melanoma 775 Colorectal Neoplasms 738 Lymphoma 723 Multiple Myeloma 716 Ovarian Neoplasms 670 Pancreatic Neoplasms 661 Lymphoma, Non-Hodgkin 656 Prostatic Neoplasms 650 Recurrence 633 Precursor Cell Lymphoblastic Leukemia-Lymphoma 579 Lung Neoplasms 556 Leukemia, Lymphocytic, Chronic, B-Cell 555 Glioblastoma 521 Leukemia 482 Lymphoma, Large B-Cell, Diffuse 438 Lymphoma, Follicular 415 Brain Neoplasms 412 Squamous Cell Carcinoma of Head and Neck 386 Stomach Neoplasms 384 Carcinoma, Renal Cell 382 Myelodysplastic Syndromes 379 Carcinoma, Hepatocellular 364 Advanced Solid Tumors 350 Lymphoma, Mantle-Cell 344 Glioma 340

Interventions

amuvatinib 1 Topotecan 1 Paclitaxel 1 Etoposide 1 Erlotinib Hydrochloride 1 Docetaxel 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00881166 2024-08-02

SGI-0470-02

Astex Pharmaceuticals, Inc.

Phase 1 Completed

Malignant Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡